利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

141 条记录 (耗时 0.037 秒)

    CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM
    11.
    发明公开
    CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM 审中-公开
    阳离子脂质和含制定分子组成

    公开(公告)号：EP1922300A2

    公开(公告)日：2008-05-21

    申请号：EP06849713.0

    申请日：2006-02-14

    申请人： Sirna Therapeutics Inc.

    发明人： CHEN, Tongqian ,  VARGEESE, Chandra ,  VAGLE, Kurt ,  WANG, Weimin ,  ZHANG, Ye

    IPC分类号： C07C217/28 ,  C07C217/84 ,  C07J41/00

    CPC分类号： C07C217/28 ,  A61K9/0073 ,  A61K9/1271 ,  A61K9/1272 ,  A61K47/543 ,  A61K47/6911 ,  C07C217/42 ,  C07C217/58 ,  C07C239/20 ,  C07J41/00 ,  C12N15/88

    摘要： The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies (e.g., monoclonal, chimeric, humanized etc.), cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, dsRNA, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double- stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, to relevant cells and/or tissues, such as in a subject or organism. Such novel cationic lipids, microparticles, nanoparticles and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism. The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).

    Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
    13.
    发明公开
    Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use 审中-公开
    新的抗雌激素类固醇和相应的药物组合物及使用方法

    公开(公告)号：EP1847548A2

    公开(公告)日：2007-10-24

    申请号：EP07015863.9

    申请日：1998-12-23

    申请人： SRI International

    发明人： Tanabe, Masato ,  Peters, Richard H ,  Chao, Wan-Ru ,  Jong, Ling

    IPC分类号： C07J41/00

    CPC分类号： C07J41/00 ,  A61K9/02 ,  C07J41/0072 ,  C07J41/0077 ,  C07J43/003

    摘要： Novel and anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependant disorders. Preferred compounds have 1,3,5-estratiene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratienes. Therapeutic methods and pharmaceutical compositions are provided as well.

    摘要翻译： 提供新颖的和抗雌激素化合物是可用于治疗多种病症，特别是雌激素依赖性病症。 优选的化合物具有1,3,5- estratiene核，并且substituiertem在与分子部分这使得有效地竞争性地阻断雌激素结合至其受体的化合物C-17或C-11位置。 特别优选的化合物是17-脱氧-1,3,5- estratienes。 提供的治疗方法和药物组合物为好。

    3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO
    14.
    发明授权
    3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO 有权
    3 - 氮基-6,7-二氧化类固醇化合物及其用途

    公开(公告)号：EP1278763B1

    公开(公告)日：2007-02-14

    申请号：EP01925262.6

    申请日：2001-04-30

    申请人： Inflazyme Pharmaceuticals, Ltd.

    发明人： RAYMOND, Jeffery, R. ,  KASSERRA, Claudia, E. ,  SHEN, Yaping

    IPC分类号： C07J41/00 ,  C07J71/00 ,  A61K31/57 ,  A61K31/58 ,  A61K31/56 ,  A61P11/06 ,  A61P37/08

    CPC分类号： C07J41/00 ,  C07J41/0005 ,  C07J41/0011 ,  C07J43/00 ,  C07J71/0047 ,  C07J71/0063 ,  Y02P20/55

    摘要： A compound of formula (I) and pharmaceutical acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R?1 and R2¿ are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen, phosphorous, silicon, and sulfur, where R?1 and R2¿ may, together with the N to which they are both bonded, form a heterocyclic structure that may be part of an organic group having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen and silicon, and where R1 may be a 2, or 3 atom chain to numeral 2 so that —N-R1 - forms part of a fused bicyclic structure to ring A; R?3 and R4¿ are selected from direct bonds to 6 and 7 respectively so as to form carbonyl groups, hydrogen, or a protecting group such that R3 and/or R4 is part of hydroxyl or carbonyl protecting group; numerals 1 through 17 each represent a carbon having substitution as described. The compounds may be formulated into pharmaceutical compositions, and used in the treatment and/or prevention of various conditions, including inflammation, asthma, an allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, solid tumors, AIDS, ischemia, and cardiac arrhythmias.